Apomorphine and the dopamine hypothesis of schizophrenia: A dilemma?

Journal of Psychiatry and Neuroscience

Volumn 26, Issue 3, 2001, Pages 203-220

  Depatie L ^a   Lal, S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE; APOMORPHINE; BIPERIDEN; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; METHYLPHENIDATE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PERGOLIDE; PIRIBEDIL; POSTSYNAPTIC RECEPTOR; PROPYLNORAPOMORPHINE; SELEGILINE; TRIHEXYPHENIDYL;

BINDING AFFINITY; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HUMAN; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; RELAPSE; REVIEW; SCHIZOPHRENIA;

APOMORPHINE; BRAIN; DOPAMINE; HUMANS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 0034972107     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. The dopamine hypothesis of schizophrenia: A review
2. Dopamine receptors and the dopamine hypothesis of schizophrenia
3. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
4. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in normal regulation and plasticity
5. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
6. A new framework for investigating antipsychotic action in humans: Lessons from PET imaging
7. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
8. 2 receptors
9. 2 receptors, yet occupy high levels of these receptors
10. Cocaine psychosis: A continuum model
11. Clinical studies with dopamine-receptor stimulants
12. Psychosis induced by central nervous system stimulants and related drugs
13. Dextroamphetamine: Evaluation of psychotomimetic properties in man
14. The antagonism of amphetamine: Induced symptomatology by a neuroleptic
15. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia
16. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate
17. Dopaminergic mechanisms in idiopathic and drug-induced psychoses
18. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies
19. Apomorphine in the evaluation of dopaminergic function in man
20. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men
21. Stereospecificity of the dopamine receptor modulating the growth hormone response to apomorphine in man
22. Effect of monoamine receptor agonists and antagonists on cyclic AMP accumulation in human cerebral cortex slices
23. Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion
24. Effect of apomorphine on schizophrenic symptoms
25. Schizophrenic symptoms improve with apomorphine
26. Side effects of subcutaneous apomorphine in Parkinson's disease
27. The clinical use of apomorphine in Parkinson's disease
28. Researches into the chemical constitutions of the opium bases. Part 1. On the action of hydrochloric acid on morphia
29. Zur antemetischen Wirkung einer Fluor-Phenothiazin-Verbindung
30. Antiemetic effectiveness of haloperidol in human volunteers challenged with apomorphine
31. A comparison of ipecac syrup and apomorphine in the immediate treatment of injestion of poisons
32. The use of apomorphine with scopolamine in labor
33. Le traitement des états anxieux par l'apomorphine
34. Treatment of alcoholism using Dent's oral apomorphine method
35. Apomorphine in the treatment of alcohol addiction: Neurophysiological and therapeutic aspects
36. Subjective and penile plethysmograph responses following aversion-relief and apomorphine aversion therapy for homosexual impulses
37. A modification of the apomorphine dumping test
38. Apomorphine and its relation to dopamine in the nervous system
39. Transient abolition of generalized photosensitive epileptic discharge in man by apomorphine, a dopamine receptor agonist
40. Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine
41. Clinical studies with apomorphine
42. Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: An open study
43. Apomorphine for motor fluctuations and freezing in Parkinson's disease
44. Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum
45. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects
46. A simple method for the study of yawning in man induced by the dopamine receptor agonist apomorphine
47. Growth hormone and schizophrenia
48. Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin
49. Apomorphine and psychopathology
50. A note on apomorphine as a sedative
51. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with and without oral dyskinesia, withdrawn from chronic neuroleptic therapy
52. Sedative, hypnotic, and antipsychotic effects of low doses of apomorphine in man
53. The use of dopamine agonists in the treatment of schizophrenia
54. Apomorphine in schizophrenia
55. Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies
56. Apomorphine has no effect on plasma homovanillic acid in schizophernic patients
57. Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients
58. Effects of intravenous administration of apomorphine on the clinical symptoms of chronic schizophrenics
59. Drug-induced parkinsonism in schizophrenic patients: Motor response and psychiatric changes after acute challenge with L-dopa and apomorphine
60. Low dose apomorphine and bromocriptine in neuroleptic-induced movement disorders
61. Apomorphine response and subtype of schizophrenia
62. Catecholaminergic drugs in chronic schizophrenia
63. Clinical effects of apomorphine in schizophrenia
64. Apomorphine and schizophrenia: Treatment, CSF, and neuroendocrine responses
65. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine
66. Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls
67. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects
68. Brain morphology, dopamine and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates
69. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia
70. Dopaminergic function in two patients with catalepsy
71. Paradoxical response to dopamine agonists in tardive dyskinesia
72. Apomorphine: Clinical studies on erectile impotence and yawning
73. Peripheral pharmacokinetics of apomorphine in humans
74. Apomorphine in Parkinson's disease
75. Similarities between neurologic effects of L-dopa and of apomorphine
76. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease
77. Subcutaneous apomorphine for Parkinsonian patients with psychiatric side effects on oral treatment
78. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment
79. Tremor inhibition in Parkinson syndrome after apomorphine administration with L-dopa and decarboxylase-inhibitor basic therapy
80. Time course of tolerance to apomorphine in parkinsonism
81. Apomorphine tolerance in Parkinson's disease: Lack of dose effect
82. Apomorphine infusion for motor fluctuations in Parkinson's disease
83. The motor response to repeated apomorphine administration in Parkinson's disease
84. Motor response following repeated apomorphine administration is reduced in Parkinson's disease
85. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease
86. Treatment of Parkinson's disease with aporphines. Positive role of growth hormone
87. Continuous subcutaneous apomorphine infusion in Parkinson's disease
88. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease
89. Subcutaneous apomorphine in Parkinson's disease
90. Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladies de Parkinson
91. External and implanted pumps for apomorphine infusion in parkinsonism
92. Subcutaneous apomorphine in Parkinson's disease
93. Side-effects of subcutaneous apomorphine in Parkinson's disease
94. Administration de l'apomorphine par voie sublinguale dans le traitement des fluctuations mortices de la maladies de Parkinson
95. Continuous apomorphine infusion for fluctuating Parkinson's disease
96. Apomorphine and diphasic dyskinesia
97. Apomorphine in treatment of Parkinson's disease: Comparison between subcutaneous and sublingual routes
98. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations
99. Subcutaneous apomorphine infusion in Parkinson's disease: Does it have a role?
100. Sublingual apomorphine: A new pharmacological approach in Parkinson's disease?
101. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations
102. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery
103. Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance
104. Subcutaneous apomorphine in the treatment of Parkinson's disease
105. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double-blind, placebo-controlled study
106. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations
107. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
108. Subcutaneous apomorphine in parkinsonian on-off oscillations
109. Apomorphine SC treatment in parkinsonian patients with long term L-dopa syndrome during L-dopa holiday
110. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations
111. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa-induced interdose dyskinesias in Parkinson's disease
112. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease
113. Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow up
114. Mental effects of L-dopa
115. Subcutaneous lisuride in Parkinson's disease: Response to chronic administration in 34 patients
116. Bromocriptine and psychosis: A literature review
117. Psychoactive properties of amantadine
118. Treatment of advanced Parkinson disease with pergolide
119. Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities
120. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
121. Visual hallucinations associated with Parkinson disease
122. Psychoses in Parkinson's disease
123. The psychic manifestations in paralysis agitans
124. Dopamine agonists in Parkinson's disease: A look at apomorphine
125. Clinical usefulness of apomorphine in movement disorders
126. Subcutaneous apomorphine in Parkinson's disease: Effective yet underused
127. The motor response to sequential apomorphine in Parkinsonian fluctuations
128. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease
129. Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease
130. Effects of amphetamine on the turnover rate of brain catecholamines and motor activity
131. A comparison of the capacities of isomers of amphetamine, deoxypipradol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta
132. Dopamine receptor pharmacology
133. 3) as a target for neuroleptics
134. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage
135. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data?
136. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in brain
137. Ontogeny of stereotyped behaviour induced by apomorphine and amphetamine in the rat
138. Some new behaviour-disrupting amphetamines and their significance
139. Behavioural effects of some morphine antagonists and hallucinogens in the rat
140. Behavior provoked by simultaneous release of dopamine and serotonin: Possible relevance to psychotic behavior
141. Turnover rate of brain 5-hydroxytryptamine increased by d-amphetamine
142. Brain noradrenergic receptors in major depression and schizophrenia
143. The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
144. Serotonergic basis of antipsychotic drug effects in schizophrenia
145. Effects of apomorphine and amphetamine on scheduled-controlled behavior: Reversal of tetrabenazine suppression and dopaminergic correlates
146. Effects of aporphine and emetine alkaloids on central dopaminergic mechanisms in rats
147. Glutamate receptor dysfunction and schizophrenia
148. The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs
149. Treatment of schizophrenia and spectrum disorders: Pharmacotherapy, psychosocial treatment and neurotransmitter interactions